

ORIGINAL ARTICLE

COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding

Pablo Demelo-Rodriguez¹ | Rubén Alonso-Beato¹ | Luis Jara-Palomares² |
Francisco Galeano-Valle¹ | Alessandra Bura-Riviere³ | Adriana Visonà⁴ |
Iria Francisco⁵ | Gemma Vidal⁶ | Antonio López-Ruiz⁷ | Manuel Monreal⁸ | on
behalf of the RIETE Investigators

¹Internal Medicine Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

²Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla, CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

³Department of Vascular Medicine, Hôpital de Rangueil, Toulouse, France

⁴Department of Vascular Medicine, Ospedale Castelfranco Veneto, Castelfranco Veneto, Italy

⁵Department of Internal Medicine, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain

⁶Department of Internal Medicine, Corporación Sanitaria Parc Taulí, Barcelona, Spain

⁷Department of Internal Medicine, Hospital Comarcal de Axarquía, Málaga, Spain

⁸Chair for the Study of Thromboembolic Disease, Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Spain, CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain

Correspondence

Francisco Galeano-Valle, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Email: paco.galeano.valle@gmail.com

Abstract

Background: Complications under anticoagulant treatment in patients with COVID-19-associated venous thromboembolism (VTE) have not been consistently reported.

Objectives: This study aimed to compare the 90-day rates of VTE recurrences and major bleeding in patients with COVID-19-associated VTE versus those with VTE without COVID-19.

Methods: We used the RIETE registry to compare the 3-month outcomes in patients with COVID-19-associated VTE versus those with VTE without COVID-19.

Results: The study included 1,747 patients with COVID-19-associated VTE and 8,711 with VTE without COVID-19. Patients with COVID-19-associated VTE were more likely to be hospitalized at baseline and to present with pulmonary embolism. During the first 90 days, 123 patients (1.17%) developed VTE recurrences, and 266 (2.54%) experienced major bleeding. Patients with COVID-19-associated VTE had a similar rate of VTE recurrences (0.9% vs 1.2%) but a higher rate of major bleeding (4.6% vs 2.1%; $P < .001$) than those without COVID-19. Multivariable analysis adjusted for competing risks showed that patients with COVID-19-associated VTE had an increased risk of major bleeding (subhazard ratio, 1.395; 95% confidence interval, 1.037-1.877). The 30-day mortality after major bleeding was 26.3% in patients with COVID-19-associated VTE and 17.7% in those without COVID-19.

Conclusion: Patients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulation. In VTE patients without COVID-19, both rates were similar. These findings highlight the importance of carefully monitoring and optimizing anticoagulation in these patients.

Coordinator of the RIETE Registry: Manuel Monreal.

RIETE Steering Committee Members: Paolo Prandoni, Benjamin Brenner and Dominique Farge-Bancel.

RIETE National Coordinators: Raquel Barba (Spain), Pierpaolo Di Micco (Italy), Laurent Bertolotti (France), Sebastian Schellong (Germany), Inna Tzorani (Israel), Abilio Reis (Portugal), Marijan Bosevski (R. Macedonia), Henri Bounameaux (Switzerland), Radovan Malý (Czech Republic), Peter Verhamme (Belgium), Joseph A. Caprini (USA), Hanh My Bui (Vietnam).

RIETE Registry Coordinating Center: S & H Medical Science Service.

© 2023 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Handling Editor: Dr Kristen Sanfilippo.

KEYWORDS

anticoagulants, COVID-19, hemorrhage, pulmonary embolism, venous thromboembolism

Essentials

- Complications of anticoagulation in COVID-19-venous thromboembolism (VTE) have not been reported.
- Patients with COVID-19-VTE versus patients with VTE without COVID-19 from the RIETE registry were included.
- In COVID-19-associated VTE, the risk of major bleeding far outweighed the risk of VTE recurrences.
- COVID-19-associated VTE had increased rates of hemoptysis, retroperitoneal, or muscular bleeding.

1 | INTRODUCTION

Patients with COVID-19 infection are at an increased risk of developing thrombotic events, mainly venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) or pulmonary embolism (PE), but also arterial thrombosis. This risk is particularly high in patients hospitalized in *intensive care units* (ICU) [1–4]. COVID-19-associated VTE shows distinctive features when compared with non-COVID-19 associated VTE, including higher D-dimer levels and a higher presence of peripheral PE, suggesting a mechanism of *in situ* pulmonary thrombosis [5–8].

In patients with COVID-19-associated VTE, current guidelines recommend prescribing anticoagulant therapy with similar therapeutic strategies than in VTE patients without COVID-19 infection [9–11]. The recommended duration of treatment is 3 to 6 months, and a recent study suggests that COVID-19 should be considered a transient risk factor for VTE [9,12]. Another recent study showed that among 233 patients with COVID-19-associated VTE the risk of recurrence was low (1.25 per 1000 person-months) [13]. However, to date, there are no studies comparing the risk for VTE recurrences and major bleeding during anticoagulation in patients with COVID-19-associated VTE versus those without COVID-19 infection.

2 | METHODS

2.1 | Patient selection

We used data from the Registro Informatizado de la Enfermedad Tromboembólica (RIETE) registry, which prospectively gathers information on patients with acute symptomatic, objectively confirmed VTE (ClinicalTrials.gov NCT02832245). The design and conduct of the RIETE registry have been previously reported [14]. Since March 2020, the registry has been updated to include information on COVID-19 infection: date of infection confirmation and diagnostic tests. All patients provided informed consent for participation in the registry. Consecutive patients diagnosed with acute VTE (DVT, PE, or both) between March 1, 2020, and June 30, 2022, were considered for inclusion in this study. COVID-19-associated VTE was defined as a VTE

event that occurred after a confirmed COVID-19 infection in the prior 30 days. Patients with incidentally found VTE and those with only superficial vein thrombosis were excluded. All patients were followed up for at least 90 days or until death if it occurred earlier. Symptomatic PE was confirmed with a positive computerized tomography (CT) of the pulmonary arteries or a high probability lung scintigraphy. DVT was confirmed using a compression ultrasound or CT of the extremities.

2.2 | Outcomes

The primary efficacy outcome was the rate of VTE recurrences within the first 90 days, and the primary safety outcome was major bleeding. In patients with suspected VTE recurrences, the diagnosis was confirmed using a CT scan, V/Q lung scintigraphy, compression ultrasound, or pulmonary arteriography. VTE recurrence in the same location as previous episode was defined if the progression of VTE to a new territory was demonstrated. Major bleeding was defined as any bleeding event that was overt and required a transfusion of 2 units or more of blood, or was retroperitoneal, spinal, intracranial, intrathecal, intrapericardial, or intraocular or was fatal. This is the definition we use in the RIETE registry, which closely resembles the definition of the International Society on Thrombosis and Haemostasis [13]. Outcomes were defined by local investigators.

2.3 | Statistical analysis

Quantitative variables were expressed as mean and standard deviation or median and interquartile range, and qualitative variables were presented through the frequency distribution. Analysis of qualitative variables was carried out using the chi-squared test, and the Mann-Whitney *U*-test was used for the quantitative variables. Normality was assessed with Kolmogorov-Smirnov test. The hazard ratio (HR) and 95% CI were calculated. A Cox regression analysis with nonparametric proportional hazards adjustment was performed for the sensitivity analysis based on cancer, sex, age, hospitalization, ICU admission, year of diagnosis (2020, 2021, and 2022), recent

TABLE 1 Baseline characteristics, VTE risk factors, presentation, treatment and outcomes of patients with COVID-19-associated VTE and VTE nonrelated to COVID-19.

Variables	COVID-19-associated VTE (%) (n = 1,747)	VTE nonrelated to COVID-19 (%) (n = 8,711)	P value
Demographics			
Sex (male), n (%)	1,109 (63.5%)	4,538 (52.1%)	<.001
Median age (interquartile range)	65 (54-75)	66 (53-77)	.253
Obesity, n (%)	361 (29.7%)	1,936 (30.1%)	.818
Patients admitted at VTE diagnosis, n (%)	1,058 (62.1%)	2,519 (30.6%)	<.001
Patients in the ICU at diagnosis, n (%)	352 (34.5%)	540 (22.2%)	<.001
Required in-hospital therapy, n (%)	564 (91.4%)	3,635 (64.5%)	<.001
Concomitant use of corticosteroids, n (%)	322 (20.8%)	693 (9%)	<.001
Recent major bleeding, n (%)	31 (1.8%)	237 (2.7%)	.022
Anemia, n (%)	492 (28.2%)	2,435 (28.1%)	.959
Platelet count <100,000/uL, n (%)	37 (2.1%)	245 (2.8%)	.095
Risk factors for VTE			
Active cancer, n (%)	153 (8.8%)	2,012 (23.1%)	<.001
Prior VTE, n (%)	74 (4.2%)	999 (11.5%)	<.001
Recent surgery (prior 2 mo), n (%)	53 (3.0%)	846 (9.7%)	<.001
Recent immobilization (prior 2 mo), n (%)	1,168 (66.9%)	2,202 (25.3%)	<.001
Initial VTE presentation			
Isolated PE, n (%)	1480 (84.7%)	4,779 (54.9%)	<.001
Isolated DVT, n (%)	322 (18.4%)	4,323 (49.6%)	<.001
Of these, distal DVT, n (%)	123 (38.2%)	856 (19.8%)	<.001
Concomitant PE and DVT, n (%)	142 (8.1%)	1,034 (11.9%)	<.001
In patients with PE			
Main pulmonary arteries involved, n (%)	52 (4.7%)	491 (12.9%)	<.001
Only subsegmental PE, n (%)	196 (11.2%)	415 (4.8%)	<.001
SBP levels <90 mm Hg, n (%)	46 (2.7%)	159 (2%)	.065
Heart rate >110 bpm, n (%)	196 (16.8%)	593 (13.2%)	.002
sPESI >1, n (%)	648 (52.4%)	2741 (54.6%)	.165
Treatment received			
Initial therapy			
• Low molecular weight heparin	1,532 (87.7%)	6,943 (79.7%)	<.001
o Enoxaparin	1,178 (76.9%)	4,881 (70.3%)	<.001
o Bemiparin	283 (18.5%)	1,291 (18.6%)	.894
o Tinzaparin	51 (3.3%)	570 (8.2%)	<.001
o Other low molecular weight heparin	20 (1.3%)	201 (2.9%)	.001
• Unfractionated heparin	96 (5.5%)	374 (4.3%)	.031

(Continues)

TABLE 1 (Continued)

Variables	COVID-19-associated VTE (%) (n = 1,747)	VTE nonrelated to COVID-19 (%) (n = 8,711)	P value
• Direct oral anticoagulants	82 (4.7%)	1045 (12%)	<.001
• Fondaparinux	10 (0.6%)	192 (2.2%)	<.001
Long-term therapy			
• Low molecular weight heparin	480 (27.5%)	2,421 (28.0%)	.685
• Vitamin K antagonists	364 (20.8%)	2,055 (23.6%)	.013
• Direct oral anticoagulants	942 (53.9%)	4,503 (51.7%)	.089
Cava vein filter, n (%)	25 (1.4%)	220 (2.5%)	.006
90-d outcomes			
VTE recurrences	16 (0.9%)	107 (1.2%)	.269
After anticoagulation discontinuation	1 (6.2%)	9 (8.4%)	1
Major bleeding	80 (4.6%)	186 (2.1%)	<.001
After anticoagulation discontinuation	0 (0%)	4 (2.1%)	.11
Death	215 (12.3%)	576 (6.6%)	<.001

DVT, deep vein thrombosis; PE, pulmonary embolism; SBP, systolic blood pressure; sPESI; simplified pulmonary embolism severity index; VTE, venous thromboembolism.

immobilization, and initial VTE presentation. Since death can interfere with the occurrence of recurrences or bleeding generating an upward bias in the estimation of the cumulative incidence, competing risk analysis using Fine and Gray method was performed. A propensity score analysis using the variables hospital admission and ICU admission was also performed. A *P* value of < .05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 25.0, IBM Corp. To plot the cumulative incidence curves and conduct competing risks regression analysis we used R Core Team (2021). R: a language and environment for statistical computing (<https://www.R-project.org/>).

3 | RESULTS


During the study period, 10,458 patients with acute VTE were recruited. Of these, 1,747 (17%) had COVID-19-associated VTE, and 8,711 had VTE nonrelated to COVID-19. Patients with COVID-19-associated VTE were more likely to be male, to be in-hospital (particularly in the ICU) at VTE diagnosis, and to be receiving corticosteroids than those without COVID-19 (Table 1). However, they were less likely to have cancer or prior VTE. As for the initial VTE presentation, patients with COVID-19-associated VTE were more

likely to present as PE, and to have peripheral PEs. Most patients in both subgroups received initial therapy with low molecular weight heparin and long-term therapy with direct oral anticoagulants.

During the first 90 days, 16 patients with COVID-19-associated VTE (0.9%) developed VTE recurrences and 80 (4.6%) had major bleeding (in the gastrointestinal tract 16, subcutaneous hematoma 14, retroperitoneal 14, muscular hematoma 10, hemoptysis 8, other sites 19). Among patients with VTE nonrelated to COVID-19, the percentages were 1.2% and 2.1%, respectively (Table 1). Patients with COVID-19-associated VTE had a similar rate of VTE recurrences than those without COVID-19 and a higher rate of major bleeding (relative risk [RR]: 2.14; 95% CI, 1.65-2.77) or death (RR: 1.86; 95% CI, 1.6-2.15) (Table 1 and Figure). Multivariable analysis of mortality, after adjusting for cancer, sex, age, hospitalization, ICU admission, year of diagnosis, recent immobilization, and initial VTE presentation revealed an HR of 1.489 (95% CI, 1.237-1.794).

After having major bleeding, the 30-day mortality was 26.3% in patients with COVID-19-associated VTE and 17.7% in those without COVID-19. Competing risk analysis of major bleeding, after adjusting for cancer, sex, age, hospitalization, ICU admission, year of diagnosis, recent immobilization, and initial VTE presentation revealed a sub-hazard ratio (SHR) of 1.395 (95% CI, 1.037-1.877) (Table 2).

Among patients who had major bleeding, those with COVID-19-associated VTE were more likely to develop hemoptysis (10% vs 1.1%, *P* = .001), retroperitoneal (17.5% vs 7.5%, *P* = .015) or muscular



	Day 7	Day 15	Day 30	Day 60	Day 90
Major bleeding (COVID & VTE)	26 (32.5%)	58 (72.5%)	73 (80%)	79 (98.7%)	80 (100%)
Major bleeding (no COVID)	66 (35.4%)	104 (55.9%)	144 (77.4%)	167 (89.8%)	186 (100%)
Recurrence (COVID & VTE)	6 (37.5%)	8 (50%)	13 (81.2%)	15 (93.7%)	16 (100%)
Recurrence (no COVID)	13 (12.1%)	26 (24.2%)	55 (51.4%)	83 (77.5%)	107 (100%)

FIGURE Ninety-day rates of major bleeding and VTE recurrences (Fine and Gray regression). Recurrences and major bleedings at day 7, 15, 30, 60, and 90. VTE, venous thromboembolism.

bleeding (12.5% vs 3.2%, $P = .008$) than patients with non-COVID-19 VTE. Location of major bleeding in patients in both subgroups is detailed in [Table 3](#).

A subanalysis of hospitalized and nonhospitalized patients was performed ([Table 4](#)). Differences in mortality among COVID and non-COVID patients were consistent regarding the hospitalization status. However, competing risk analysis showed a higher risk of bleeding in hospitalized patients with COVID-19-associated VTE (SHR, 1.607; 95% CI, 1.099-2.348), with no differences in nonhospitalized patients (SHR, 1.061; 95% CI, 0.588-1.914). A propensity score analysis using the variables hospital admission and ICU admission is included in the [Supplementary Materials](#).

4 | DISCUSSION

Our findings reveal that patients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulant therapy. One in every 4 patients (26.3%) who bled, died within the first 30 days. Thus, the clinical relevance of major bleeding in these patients should not be underestimated. In patients with VTE and without COVID-19, the rates of

major bleeding and VTE recurrences were closer. The higher risk for major bleeding in patients with COVID-19 was confirmed on multi-variable analysis, after adjusting for potential confounders, including year of COVID-19 diagnosis. Thus, COVID-19 might be an independent risk factor for major bleeding in these patients. This increased risk of bleeding in COVID-19 patients is only observed in hospitalized patients, most likely due to the inflammatory status of patients with more severe forms of the disease. To our knowledge, this is the largest study including patients with COVID-19-associated VTE, and the first

TABLE 2 Competing risks Fine and Gray regression.

Competing risks Fine and Gray regression					
Event: 90-d major bleeding					
Competing event: 90-d mortality					
Variables	SHR	95% CI	z-value	P (z)	Coefficient
COVID-19 associated VTE	1.395	1.037-1.877	2.21	0.027	0.333

Variables included in the model: cancer, sex, age, hospitalization, ICU admission, year of diagnosis, recent immobilization and initial VTE presentation. CI, confidence interval; SHR, subhazard ratio; VTE, venous thromboembolism.

TABLE 3 Location of major bleeding in patients with COVID-19-associated VTE and VTE nonrelated to COVID-19.

Location of major bleeding	COVID-19-associated VTE (%) (n = 80)	VTE nonrelated to COVID-19 (%) (n = 186)	P value
Gastrointestinal, n (%)	16 (20%)	67 (36%)	.010
Hematoma, n (%)	14 (17.5%)	27 (14.5%)	.537
Intracranial, n (%)	8 (10%)	29 (15.6%)	.227
Retroperitoneal, n (%)	14 (17.5%)	14 (7.5%)	.015
Urinary, n (%)	2 (2.5%)	16 (8.6%)	.069
Muscular, n (%)	10 (12.5%)	6 (3.2%)	.008
Hemoptysis, n (%)	8 (10%)	2 (1.1%)	.001
Epistaxis, n (%)	2 (2.5%)	2 (1.1%)	.586
Hemopericardium, n (%)	0 (0%)	1 (0.5%)	1
Hemothorax, n (%)	1 (1.3%)	1 (0.5%)	.512
Menorrhagia, n (%)	0 (0%)	4 (2.2%)	.319
Other locations, n (%)	5 (6.3%)	17 (9.1%)	.433

VTE, venous thromboembolism.

comparing rates of VTE recurrences and major bleeding during the course of anticoagulation between COVID-19-associated VTE and non-COVID-19 VTE.

The bleeding risk has been an issue of concern in COVID-19 patients, particularly at the beginning of the pandemic [15,16]. Observational studies reported a higher risk for major bleeding in patients with COVID-19 receiving intermediate or therapeutic doses of thromboprophylaxis during hospital admission [15–18]. Similarly to

our findings, a recent observational study comparing 79 patients with COVID-19-associated PE to 150 patients with PE without COVID-19 revealed that COVID-19 patients had a higher risk of bleeding and a low risk of recurrence [19]. Our study reveals that in patients with COVID-19-associated VTE, the rate of major bleeding is much higher than the rate of VTE recurrences. Thus, anticoagulant therapy should be carefully chosen and checked, and treatment duration should be optimized in these patients.

Our study has several limitations that need to be discussed. First, since RIETE is an observational study, treatment choice was made by the attending physicians (there is no adjudication committee). Second, due to the characteristics of the registry, some information regarding VTE infection, specifically antiviral treatment, and symptoms onset was missing. Third, we decided to include all patients with COVID-19-associated VTE, whether they were hospitalized due to COVID-19 infection or home; these populations and their expected outcomes might be different. Fourth, sociocultural aspects of health care (which include structural racism for example) were not included in the study and might impact in the results, due to the social determinants of health impacts in health outcomes.

5 | CONCLUSION

Patients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulation. In VTE patients without COVID-19, both rates were closer. Since one in every 4 patients who bled died within the first 30 days, physicians taking care of patients with COVID-19 associated VTE should periodically monitor these patients during anticoagulation. These findings require external validation.

TABLE 4 Subanalysis of hospitalized and nonhospitalized patients.

Variables	Hospitalized COVID-19-associated-VTE vs VTE without COVID-19	Nonhospitalized COVID-19-associated-VTE vs VTE without COVID-19
Univariate analysis		
Recurrences	HR 0.733 (95% CI, 0.384-1.1401)	HR 0.309 (95% CI, 0.0756-1.268)
Major bleeding	HR 1.975 (95% CI, 1.392-2.802)	HR 1.247 (95% CI, 0.726-2.142)
Death	HR 1.472 (95% CI, 1.205-1.798)	HR 1.616 (95% CI, 1.192-2.190)
Multivariable analysis (Cox regression)		
Major bleeding	HR 1.607 (95% CI, 1.072-2.408)	HR 1.061 (95% CI, 0.595-1.892)
Death	HR 1.633 (95% CI, 1.292-2.064)	HR 1.478 (95% CI, 1.065-2.051)
Competing risk analysis (Fine and Gray regression)		
Major bleeding	SHR 1.607 (95% CI, 1.099-2.348)	SHR 1.061 (95% CI, 0.588-1.914)

Multivariable: Cox regression analysis adjusted for cancer, sex, age, hospitalization, ICU admission, year of diagnosis (2020, 2021, 2022), recent immobilization and initial VTE presentation. Competing risk analysis: Fine and Gray analysis using death as competing risk after adjusting for cancer, sex, age, year of diagnosis, recent immobilization and initial VTE presentation.

CI, confidence interval; HR, hazard ratio; SHR, subhazard ratio; VTE, venous thromboembolism.

APPENDIX

Members of the RIETE Group

SPAIN: Adarraga MD, Alberich-Conesa A, Amado C, Amorós S, Arcelus JI, Ballaz A, Barba R, Barbagelata C, Barrón M, Barrón-Andrés B, Blanco-Molina A, Botella E, Carrero R, Casado I, Criado J, del Toro J, De Ancos C, De Juana-Izquierdo C, Demelo-Rodríguez P, Díaz-Brasero AM, Díaz-Pedroche MC, Díaz-Peromingo JA, Dubois-Silva A, Escribano JC, Espósito F, Falgá C, Farfán-Sedano AI, Fernández-Capitán C, Fernández-Jiménez B, Fernández-Muixi J, Fernández-Reyes JL, Font C, Francisco I, Galeano-Valle F, García MA, García de Herreros M, García-Bragado F, García-Ortega A, Gavín-Sebastián O, Gil-Díaz A, Gil-Hernández A, Gómez-Cuervo C, Gómez-Mosquera AM, González-Martínez J, Grau E, Guirado L, Gutiérrez J, Hernández-Blasco L, Jara-Palomares L, Jaras MJ, Jiménez D, Jou I, Joya MD, Lacruz B, Lalueza A, Lainez-Justo S, Lecumberri R, León-Ramírez JM, Lobo JL, López-De la Fuente M, López-Jiménez L, López-Miguel P, López-Núñez JJ, López-Reyes R, López-Ruiz A, López-Sáez JB, Lorente MA, Lorenzo A, Lumbierres M, Madridano O, Maestre A, Mas-Maresma L, Marcos M, Martín-Guerra JM, Martín-Martos F, Mellado M, Mena E, Mercado MI, Moisés J, Monreal M, Muñoz-Blanco A, Muñoz-Gamito G, Nieto JA, Núñez-Fernández MJ, Osorio J, Otalora S, Pacheco-Gómez N, Paredes-Ruiz D, Parra P, Pedrajas JM, Pérez-Ductor C, Pérez-Jacoiste A, Pérez-Pérez JL, Peris ML, Pesce ML, Porras JA, Poyo-Molina J, Puchades R, Riera-Mestre A, Rivera-Cívico F, Rivera-Gallego A, Roca M, Rubio CM, Rosa V, Rodríguez-Cobo A, Ruiz-Giménez N, Ruiz-Ruiz J, Salgueiro G, Sancho T, Sendín V, Sigüenza P, Soler S, Suriñach JM, Tiberio G, Tolosa C, Torres MI, Trujillo-Santos J, Uresandi F, Usandizaga E, Valle R, Varona JF, Vela JR, Vela L, Vidal G, Villalobos A, Villares P, AUSTRIA: Ay C, Nopp S, Pabinger I, BELGIUM: Engelen M, Martens C, Verhamme P, BRAZIL: Yoo HHB, COLOMBIA: Arguello JD, Montenegro AC, Roa J, CZECH REPUBLIC: Hirmerova J, Malý R, FRANCE: Accassat S, Bertolotti L, Bura-Riviere A, Catella J, Chopard R, Couturaud F, Espitia O, Grange C, Leclercq B, Le Mao R, Mahé I, Moustafa F, Plaisance L, Poenou G, Sarlon-Bartoli G, Suchon P, Versini E, GERMANY: Schellong S, ISRAEL: Braester A, Brenner B, Kenet G, Najib D, Tzoran I, IRAN: Farrashi M, Sadeghipour P, ITALY: Basaglia M, Bilora F, Bortoluzzi C, Brandolin B, Ciammaichella M, Colaizzo D, Dentali F, Di Micco P, Grandone E, Imbalzano E, Merla S, Pesavento R, Prandoni P, Scarinzi P, Siniscalchi C, Taflaj B, Tufano A, Visonà A, Vo Hong N, Zalunardo B, LATVIA: Kigitovica D, Skride A, Zaichenko A, PORTUGAL: Fonseca S, Manuel M, Meireles J, REPUBLIC OF MACEDONIA: Bosevski M, Eftimova A, Zdraveska M, SWITZERLAND: Bounameaux H, Mazzolai L, UNITED KINGDOM: Aujayeb A, USA: Caprini JA, Weinberg I, VIETNAM: Bui HM.

ACKNOWLEDGMENTS

We express our gratitude to **Sanofi Spain** and **ROVI** for supporting this Registry with an unrestricted educational grant. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support.

AUTHOR CONTRIBUTIONS

P.D.R., R.A.B, L.J.P., F.G.V., and M.M. conceptualized the study. P.D.R., R.A.B, L.J.P., and M.M. provided the methodology. P.D.R., R.A.B, L.J.P., and M.M. validated the study. P.D.R., R.A.B, L.J.P., F.G.V., A.B.R., A.V., I.F., G.V., A.L.R., M.M., and the RIETE Investigators investigated the study; P.D.R., R.A.B, and M.M. curated the data., P.D.R., R.A.B, L.J.P., and M.M. prepared the original draft. P.D.R., R.A.B, L.J.P., F.G.V., A.B.R., A.V., I.F., G.V., A.L.R., M.M., and the RIETE Investigators reviewed and edited the manuscript. M.M. supervised the study. M.M. administered the project. All authors have read and agreed to the published version of the manuscript.

FUNDING

The study was supported by Sanofi Spain and ROVI with an unrestricted educational grant. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

RELATIONSHIP DISCLOSURE

There are no competing interests to disclose.

REFERENCES

- [1] Jiménez D, García-Sánchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. *Chest*. 2021;159:1182–96.
- [2] Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. *Thromb Res*. 2020;192:23–6.
- [3] Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145–7.
- [4] Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. 2020;18:1995–2002.
- [5] Fernández-Capitán C, Barba R, Díaz-Pedroche MDC, Sigüenza P, Demelo-Rodríguez P, Siniscalchi C, et al. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. *Semin Thromb Hemost*. 2021;47:351–61.
- [6] Ortega-Paz L, Talasaz AH, Sadeghipour P, Potpara TS, Aronow HD, Jara-Palomares L, et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. *Semin Thromb Hemost*. 2022.
- [7] Kwee RM, Adams HJA, Kwee TC. Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. *Eur Radiol*. 2021;31:8168–86.
- [8] Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. *N Engl J Med*. 2020;383:120–8.
- [9] Barnes GD, Burnett A, Allen A, Ansell J, Blumenstein M, Clark NP, et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. *J Thromb Thrombolysis*. 2022;54:197–210.

- [10] Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. *Lancet Oncol.* 2022;23:e334–47.
- [11] Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. *Chest.* 2022;162:213–25.
- [12] Jara-Palomares L, Bikdeli B, Jiménez D, Muriel A, Martín Del Pozo M, Demelo-Rodríguez P, et al. Rate of recurrence after discontinuing anticoagulation therapy in patients with COVID-19-associated venous thromboembolism. *JAMA Intern Med.* 2022;182:1326–8.
- [13] Alonso-Beato R, Lago-Rodríguez MO, López-Rubio M, Gómez-Tórtola A, García-Fernández-Bravo I, Oblitas CM, et al. Risk of thrombosis recurrence among patients with COVID-19- and surgery-associated venous thromboembolism. *Rev Clin Esp.* 2023;223:255–61.
- [14] Bikdeli B, Jimenez D, Hawkins M, Ortiz S, Prandoni P, Brenner B, et al. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). *Thromb Haemost.* 2018;118:214–24.
- [15] Demelo-Rodríguez P, Farfán-Sedano AI, Pedrajas JM, Llamas P, Sigüenza P, Jaras MJ, et al. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. *J Thromb Haemost.* 2021;19:1981–9.
- [16] Kessler C, Stricker H, Demundo D, Elzi L, Monotti R, Bianchi G, et al. Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis. *J Thromb Thrombolysis.* 2020;50:833–6.
- [17] Demelo-Rodríguez P, Galeano-Valle F, Ordieres-Ortega L, Siniscalchi C, Martín Del Pozo M, Fidalgo Á, et al. Validation of a prognostic score to identify hospitalized patients with COVID-19 at increased risk for bleeding. *Viruses.* 2021;13:2278.
- [18] Poli D, Antonucci E, Ageno W, Prandoni P, Barillari G, Bitti G, et al. Thromboembolic complications in COVID-19 patients hospitalized in Italian ordinary wards: data from the multicenter observational START-COVID register. *TH Open.* 2022;6:e251–6.
- [19] de Cossio S, Paredes-Ruiz D, Gómez-Cuervo C, González-Olmedo J, Lalueza A, Revilla Y, et al. Clinical differences and outcomes of COVID-19 associated pulmonary thromboembolism in comparison with non-COVID-19 pulmonary thromboembolism. *J Clin Med.* 2022;11:6011.